CompanyANNXNasdaqBrisbane, CA

Annexon, Inc.

Annexon develops targeted immunotherapies that inhibit C1q-driven complement activation for neuroinflammatory diseases.

SEC EDGAR ClinicalTrials.gov annexonbio.com

424B4Sep 28Latest SEC filing

Sep 8Latest story

September 2026

Annexon registers Phase 3 extension study of vonaprument for geographic atrophy

Sep 8Trial updateAnnexon, Inc.vonaprument

August 2026

Annexon posts results for completed Phase 2a ANX005 study in Huntington's disease

Aug 25Trial updateAnnexon, Inc.ANX005

Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarter

Aug 12Quarterly updateAnnexon, Inc.

Annexon adds retinal surgeon Mark Blumenkranz to board as Muneer Satter departs

Aug 10PeopleAnnexon, Inc.

Annexon reports early data from first 10 GBS FORWARD study patients

Aug 6Regulatory decisionAnnexon, Inc.

July 2026

Annexon sets up $200 million loan facility with Oxford Finance

Jul 30FinancingAnnexon, Inc.

June 2026

Annexon posts results for ANX005 Phase 2 wAIHA study, completed with 7 participants

Jun 30Trial updateAnnexon, Inc.ANX005